I agree with your last post Emannow. I believe that Mark Foley has made significant changes and fired many on his team to realign their biz. This was not an easy time for him and these are tough decisions that needed to be made. I feel their pricing is very generous and exactly where it needs to be to gain market share. In my experience, every large account that is highly profitable knows how to price their NTs. We do not allow Revance, allergan, galderma, evolus, merz to dictate pricing for us. We know what we need to make to stay happy and we price it accordingly with a good feel for price elasticity and profit/injector/hour for our geography. If we get too greedy we will lose patients...we understand this dynamic. Market forces in this business tend to be efficient as word of mouth on pricing and injector skill spreads quickly. It's why all top national accounts tend to have similar unit pricing over time in each geography. With regard to Daxxify, we didn't have a feel for duration in frontalis and lateral canthal lines at the time of product launch in December 2022. We had to figure it out and we did. Pricing was initially much higher with high minimums to get to lower pricing tiers on Daxi: the lowest tier at launch was $330/vial and the highest was $420/vial.
I am using 2 concentrations of Daxi in my practice: 1 that lasts longer and runs 30 to 50% more expensive and one that lasts similar to slightly longer than Botox but is 5 to 10% cheaper. Clients have been trying out both and deciding for themselves which one they prefer. I have an 86% conversion rate of Botox patients to Daxxify once they trial it. Half of the remaining 14% that go back to Botox go back because they had a big alle coupon with cost savings for Botox or bought a botox rebate in the past. They don't go back to Botox because they didn't like Daxi. We are seeing some 7 to 10% that don't get the duration benefit of Daxxify and we see this variability across most NTs. I can't explain it.
Today, the top Daxi injectors have a much better feel for duration of action and aesthetic in all facial injection zones and also have highly competitive pricing at $275/vial since the September price drop. Injectors that are new to Daxi are benefitting from the learnings of the early adopters.
I am also hearing about rebates coming and a loyalty program launching this year that will further aid in branding and consumer marketing in addition to patient treatment cost savings.
